Highly-Efficient Purification of Native Polyhistidine-Tagged Proteins by Multivalent NTA-Modified Magnetic Nanoparticles by Kim, Jason S. et al.
Highly-Efficient Purification of Native Polyhistidine-tagged
Proteins by Multivalent NTA-modified Magnetic Nanoparticles
Jason S. Kim†, C. Alexander Valencia‡, Rihe Liu‡,*, and Wenbin Lin†,*
†Department of Chemistry, University of North Carolina, Chapel Hill, NC 27599
‡School of Pharmacy and Carolina Center for Genome Sciences, University of North Carolina, Chapel Hill,
NC 27599
Abstract
A new bis-nitrilotriacetic acid (NTA) chelate with catechol anchor was synthesized and immobilized
on superparamagnetic iron oxide nanoparticles. When loaded with Ni(II), these bis-NTA-
immobilized nanoparticles were shown to bind polyhistidine (His×6-tagged) fusion proteins in their
native, folded conformations that commercial microbeads failed to bind under identical conditions.
Control experiments with a mono-NTA chelate immobilized on iron oxide nanoparticles indicate a
similarly high affinity for His×6-tagged native proteins, suggesting that the high density of the mono-
NTA chelate presented by the nanoparticles allows the binding of the His×6-tag to more than one
Ni-NTA moiety on the surface. This study shows that the multivalency strategy can be utilized to
enhance the binding of His×6-tagged proteins in their native, folded conformations. We further
demonstrated the selective purification of His×6-tagged proteins from crude cell lysates by using the
Ni(II)-loaded iron oxide nanoparticles. The present platform is capable of efficient purification of
His×6-tagged proteins that are expressed at low levels in mammalian cells. This work thus presents
a novel nanoparticle-based high-capacity protein purification system with shorter incubation times,
proportionally large washes, and significantly smaller elution volumes compared to commercially
available microbeads.
INTRODUCTION
As we enter the proteomic era, there is an ever-increasing need for efficient protein purification
techniques that allow for direct isolation of proteins from cell lysates.(1) Among many
currently used protein purification strategies,(2) immobilized metal affinity chromatography
(IMAC) has emerged as one of the most powerful techniques for the purification of recombinant
proteins.(3) In the most common IMAC implementation, a His×6 tag that comprises of six
consecutively placed histidine residues is incorporated into the C- or N-terminus of a
recombinant protein. The His×6 tag binds strongly to a divalent metal chelate such as the Ni
(II) nitrilotriacetate complex (Ni-NTA) which is in turn immobilized on a resin. It is believed
that four of the six coordination sites on the octahedral Ni(II) center are occupied by the NTA
ligand and the remaining coordination sites are occupied by two of the six imidazole moieties
in the His×6 tag.(4)
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The IMAC strategy allows the purification of His×6-tagged proteins in one or two steps to
achieve a moderate degree of purity. Moreover, the His×6 tag is relatively small and generally
does not interfere with the native structure and function of the tagged protein. Since its
discovery in late 1980s, Ni-NTA based IMAC has been widely used for purifying recombinant
proteins, and many His×6-tagged proteins are now commercially available. While this strategy
has proven to be largely successful, a significant percentage of recombinant proteins remain
difficult to purify by IMAC.(5) Low protein expression is a key contributor to such difficulties
as the target protein concentration may be less than 0.1% of the cleared crude lysate when
overexpressed in E. coli, and much lower when overexpressed in mammalian cells. Numerous
functionally active proteins can only be expressed in mammalian cells, which poses new
challenges to protein purification techniques. The target protein structure may also add to
purification difficulties by blocking the His×6-tag from the Ni-NTA moiety on the surface of
microbeads. Consequently, commercial Ni-NTA resins cannot capture a large number of
His×6-tagged proteins under native conditions. To overcome this problem, purification under
denaturing conditions has been used to gain full access to the His×6-tag, but overall protein
purification efficacy significantly decreases because of the unreliability and inefficiency of in
vitro protein re-folding to their native functional conformations.
Significant efforts have been devoted to gaining a better understanding of the Ni-NTA/His×6-
tag interactions and thus improving the IMAC protein purification efficiency over the past few
years. The strength of the Ni-NTA/His×6-tag interaction was, for example, recently assessed
using scanning force microscopic techniques.(6) Ebright et al. elegantly demonstrated
enhanced binding of the His×6-tag to a bivalent Ni-NTA system over a monovalent Ni-NTA
control using fluorescence anisotropy and fluorescence resonance energy transfer
measurements.(7) Piehler et al. has further studied the enhanced affinity of multivalent Ni-
NTA-derived molecules toward the histidine tag in great detail.(8,9,10) In the present work,
we wish to design a superparamagnetic iron oxide immobilized bivalent Ni-NTA chelate
system with the aim of improving IMAC purification of His×6-tagged proteins by
strengthening the interactions between the His×6-tag and the bivalent Ni-NTA chelate. The
bis-Ni-NTA-immobilized nanoparticles were shown to be capable of binding His×6-tagged
proteins in their native, folded conformations that failed to bind commercial microbeads under
identical conditions. We have demonstrated that the present system is superior to commercial
magnetic beads in binding to His×6-tagged proteins and is useful for isolating target proteins
that are overexpressed at low levels in the mammalian cells. Control experiments with a mono-
NTA chelate immobilized on iron oxide nanoparticles indicated a similarly high affinity for
His×6-tagged proteins, suggesting that the very high density of the mono-NTA chelate
presented by the nanoparticles allows the binding of the His×6-tag to more than one NTA
moiety on the surface. Thus, this work demonstrates that the multivalency strategy can be
utilized to enhance the binding of His×6-tagged proteins in their native, folded conformations.
MATERIALS AND METHODS
General
Nα,Nα-bis(carboxymethyl)-L-lysine was purchased from Fluka. 2-(3,4-Bis-benzyloxyphenyl)-
ethylamine-trifluoroacetate-salt (Bn-DA-TFA) and Nα,Nα-bis(carboxymethyl)-L-lysine
tribenzyl ester-trifluoroacetate-salt (Bn-NTA-lys-TFA) were prepared from literature
procedures.(1,11) All other chemicals were purchased from Sigma-Aldrich and used as
received unless otherwise noted. Carboxy-terminated magnetic microparticles were purchased
from Bangs Laboratories, Inc. Purified recombinant His×6-endostatin (His×6-rmES) was
purchased from Calbiochem. Recombinat human His×6-ubiquitin (His×6-Ub) and mouse
His×6-ubiquitin C-terminal hydrolase L-1 (His×6-UCH-L1) were from Boston Biochem. 1H
and 13C{1H} NMR spectra were obtained on a Bruker 400MHz AVANCE or Bruker 400MHz
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DRX. Mass spectra were obtained from Voyager DE-Pro MALDI-MS or HP/Agilent LC/Ion-
trap MS in the Department of Chemistry at Duke University. Liquid scintillation counting
experiments are performed on a Tri-Carb 2900TR Liquid Scintillation Analyzer. SDS-PAGE
gels were quantified using the AlphaEaseFC program. Transmission Electron Microscopy
(TEM) images were taken with a JEM-100CXII transmission electron microscope at 100 KV.
Synthesis of dimethyl 5-(3,4-bis(benzyloxy)phenethylcarbamoyl)benzene-1,3-dioate (1)
To a stirring solution of benzene-1,3,5-tricarbonyltrichloride (1.7 g, 6.40 mmol) in dry
CH2Cl2 (170 mL) at 0°C was added Bn-DA-TFA (0.536 g, 1.20 mmol) in dry CH2Cl2 (100
mL) dropwise over 5 hours. The solution was allowed to warm to room temperature. The
solvent was removed under reduced pressure to produce a white residue. Methanol was added
and stirred for a few hours. The excess methanol was removed under reduced pressure to
produce a white solid. The product was isolated using flash column chromatography (ethyl
acetate/hexanes, 2:3 v/v; Rf = 0.4). The solvents were removed under reduced pressure to yield
a white solid of 1 (0.225 g, 0.408 mmol, 34.0% yield). 1H NMR (400MHz, CDCl3): 8.75 (s,
1H), 8.52 (s, 2H), 7.40 (d, 4H), 7.29 (m, 6H), 6.90 (d, 1H), 6.81 (s, 1H), 6.72 (d, 1H), 5.11 (s,
2H), 5.01 (s, 2H), 3.92 (s, 6H), 3.64 (q, 2H), 2.83 (t, 2H); 13C NMR (CDCl3, 100 MHz) δ
165.4, 165.3, 149.0, 147.6, 137.2, 137.0, 135.4, 132.9, 132.0, 131.9, 130.9, 128.3, 127.7, 127.2,
121.5, 115.5, 115.3, 71.3, 71.2, 52.4, 41.4, 34.9, 31.5; MALDI-MS: [M+H]+ m/z 554.0 (calcd
554.6); [M+Na]+, m/z 577.2 (calcd 576.6); [M+K]+ m/z 592.8 (calcd 592.7).
Synthesis of 5-(3,4-bis(benzyloxy)phenethylcarbamoyl)benzene-1,3-dioic acid (2)
To a stirring solution of 1 (0.160, 0.289 mmol) in acetone (6 mL) was added 1N NaOH (4 mL).
After 3 hours, complete deprotection was confirmed by TLC. The solution was acidified to pH
3 using 1N HCl. The solvent was removed and the product was stirred in H2O. The precipitate
of 2 was collected by suction filtration and recrystallized in acetone (0.145 g, 0.276 mmol,
95.5% yield). 1H NMR (400MHz, MeOD): 8.42 (s, 1H), 8.21 (s, 2H), 7.15−6.90 (m, 10H),
6.67 (s, 1H), 6.62 (d, 1H), 6.49 (d, 1H), 4.73 (s, 4H), 3.28 (t, 2H), 2.54 (t, 2H); 13C NMR
(DMSO, 100 MHz) δ 166.4, 164.6, 148.3, 146.8, 137.5, 137.4, 135.5, 132.7, 132.2, 132.0,
131.8, 128.4, 127.8, 127.7, 127.6, 127.5, 121.2, 115.2, 114.8, 70.3, 70.2, 41.1, 34.4; MALDI-
MS: [M+H]+ m/z 525.9 (calcd 526.6).
Synthesis of 5-(3,4-bis(benzyloxy)phenethylcarbamoyl)benzene-1,3-benzyl-NTA-lysine (3)
The diacid 2 (0.140 g, 0.266 mmol) was stirred in dry CH2Cl2 (13 mL) to form a cloudy
suspension. 0.40 mL of SOCl2 was slowly added and stirring continued at 50 °C for 6 hours
to form a clear solution. The solvent was removed under reduced pressure to give the 5-(3,4-
bis(benzyloxy)phenethylcarbamoyl)-benzene-1,3-dioyl dichloride intermediate which was
used without further purification.
To a stirring mixture of Bn-NTA-lys-TFA (0.408 g, 0.632 mmol), TEA (0.5 mL), and
CHCl3 (5 mL) was added a solution of 5-(3,4-bis(benzyloxy)phenethylcarbamoyl)
benzene-1,3-dioyl dichloride in CHCl3 (10 mL) dropwise at 0 °C. The reaction was allowed
to warm to room temperature and stir overnight. After removal of solvents under reduced
pressure, column chromatography (ethyl acetate/hexanes, 3:2 v/v; Rf = 0.5) was used to isolate
a pure white solid of 3 (0.281 g, 0.181 mmol, 67.9% yield). 1H NMR (CDCl3, 400 MHz) δ
8.33 (s, 3H), 7.41−7.25 (m, 35H), 6.95 (t), 6.86 (d, 2H), 6.80 (s, 2H), 6.69 (d, 2H), 5.10 (s,
8H), 5.06 (s, 2H), 4.98 (s, 4H), 3.68 (s, 4H), 3.59 (t, 4H), 3.46 (t, 1H), 3.32 (t, 2H) 2.75 (t, 4H),
1,69−1.24 (m, 6H); 13C NMR (CDCl3, 100 MHz) δ 172.8, 171.7, 166.3, 149.3, 148.0, 137.6,
137.5, 135.9, 135.8, 135.6, 135.4, 132.4, 128.8, 128.7, 128.6, 128.5, 128.0, 127.7, 121.7, 116.2,
115.9, 71.6, 66.8, 66.7, 64.5, 53.1, 40.2, 35.4, 29.9, 28.5, 23.1; MALDI-MS: [M+H]+ m/z
1556.3 (calcd 1555.8); [M+Na]+, m/z 1577.5 (calcd 1577.8); [M+K]+, m/z 1593.1 (calcd
1593.9).
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Synthesis of 5-(3,4-bis(hydroxy)phenethylcarbamoyl)benzene-1,3-NTA-lysine (4)
3 (0.043 g, 0.052 mmol) was dissolved in 1.5 mL of CHCl3 and 6 mL of MeOH and placed in
a Parr flask with 15 mg Pd/C (10%). The mixture was shaken in a Parr reactor for 24 hours
under H2 (60 psi). Upon complete deprotection, the palladium catalyst was filtered off using
Celite and solvent removed under reduced pressure. The product was purified by
recrystallization in MeOH/CH2Cl2 to give 4 in a quantitative yield. 1H NMR (MeOD, 400
MHz) δ; 8.29 (s, 3H), 6.60 (s, 1H), 6.59 (s, 1H), 6.47 (d, 2H), 3.71−3.21 (m, 16H), 2.68 (t,
2H), 1.63−1.45 (m, 8H), 1.18 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ; 174.1, 173.0, 168.6,
146.7, 144.7, 136.6, 132.0, 130.0, 121.1, 117.0, 116.4, 66.9, 54.3, 43.1, 40.7, 35.9, 29.8, 29.8,
24.4; MALDI-MS: [M]+, m/z 833 (calcd 833.8); [M+Na]+, m/z 856 (calcd 856.8).
Synthesis of methyl 3,5-bis(3,4-bis(benzyloxy)phenethylcarbamoyl)benzoate (5)
To a stirring solution of benzene-1,3,5-tricarbonyltrichloride (0.320 g, 1.20 mmol) in dry
CH2Cl2 (170 mL) at 0 °C was added Bn-DA-TFA (0.536 g, 1.20 mmol) in dry CH2Cl2 (100
mL) dropwise over 5 hours. The solution was allowed to warm to room temperature. The
solvent was removed under reduced pressure to produce a white residue. Methanol was added
and allowed to stir for a few hours. The excess methanol was removed under reduced pressure
to produce a white solid. The product was isolated using silica flash column chromatography
(ethyl acetate/hexanes, 1:1 v/v; Rf = 0.4). The solvents were removed under reduced pressure
to yield a white solid of 5 (0.298 g, 0.349 mmol, 29.0% yield). 1H NMR (CDCl3, 400 MHz)
δ 8.44 (s, 2H), 8.28 (s, 1H), 7.45−7.25 (m, 20H), 6.88 (d, 2H), 6.81 (s, 2H), 6.71 (d, 2H), 6.56
(t, 2H), 5.10, (s, 8H), 3.88 (s, 3H), 3.60 (q, 4H), 2.80 (t, 4H); 13C NMR (CDCl3, 100 MHz)
δ 165.6, 165.3, 148.7, 147.4, 136.9, 136.8, 135.1, 131.9, 130.5, 130.3, 129.6, 128.2, 127.6,
127.2, 127.1, 121.4, 115.4, 115.0, 71.1, 52.2, 41.3, 34.7; MALDI-MS: [M+Na]+, m/z 877.0
(calcd 878.0); [M+K]+, m/z 893.0 (calcd 894.1).
Synthesis of 3,5-bis(3,4-bis(benzyloxy)phenethylcarbamoyl)benzoic acid (6)
5 (0.250 g, 0.292 mmol) was stirred in a solution of 3 mL of acetone and 1 mL of 1M NaOH
overnight. The solution was acidified to pH 3 using 1N HCl, added dropwise. The solvent was
removed and the product was stirred in H2O. The precipitate was collected by vacuum filtration
to give 6 in quantitative yield. 1H NMR (MeOD, 400 MHz) δ 8.53 (s, 2H), 8.37 (s, 1H), 7.40
−7.20 (m, 20H), 6.93 (s, 2H), 6.91 (s, 2H), 6.76 (d, 2H), 5.03 (s, 8H), 3.54 (t, 4H), 2.81 (t,
4H); 13C NMR (CDCl3, 100 MHz) δ 169.2, 164.9, 150.4, 148.9, 138.9, 138.8, 136.3, 134.3,
131.9, 129.8, 129.5, 128.9 128.8, 123.1, 117.2, 116.9, 72.7, 72.5, 42.8, 37.0; MALDI-MS: [M
+Na]+, m/z 863.4 (calcd 864.0).
Synthesis of benzyl 6-(N3,N5-bis(3,4-bis(benzyloxy)phenethyl)benzene-1,3,5-
tricarboxamido)-2-(bis(((benzyloxy)carbonyl)methyl)amino)hexanoate (7)
A mixture of Bn-NTA-lys-TFA (0.060 g, 0.071 mmol), 6 (0.075 g, 0.142 mmol), and HOBt
(0.010 g, 0.074 mmol) was stirred in 3 mL anhydrous DMF for 5 minutes.
Dicyclohexylcarbodiimide (0.015 g, 0.073 mmol) was added and the mixture was allowed to
stir overnight. The solvents were removed under reduced pressure. The product 7 was isolated
with silica gel flash column chromatography (ethyl acetate/hexanes, 3/2 v/v; Rf = 0.4). Yield:
0.094 g (97.7%). 1H NMR (CDCl3, 400 MHz) δ 8.43 (s, 1H), 8.41 (s, 2H), 7.50−7.26 (m, 40H),
7.04 (s, 3H), 6.87 (s, 1H), 6.85 (d, 1H), 6.72 (d, 1H), 5.12 (s, 8H), 5.07 (s, 8H), 3.74 (s, 8H),
3.59 (t, 2H), 3.51 (t, 2H), 3.35 (t, 4H), 2.79 (t, 2H), 1.75−1.28 (m, 12H); 13C NMR (CDCl3,
100 MHz) δ 172.5, 171.5, 165.9, 148.9, 147.6, 137.2, 137.1, 135.3, 132.0, 128.5, 128.4, 128.3,
128.2, 128.1, 127.7, 127.4, 127.3, 121.5, 115.7, 115.2, 71.3, 66.5, 66.4, 64.0, 52.8, 41.5, 39.9,
35.0, 27.9, 25.5, 24.8; MALDI-MS: [M+H]+, m/z 1356.4 (calcd 1355.6); [M+Na]+, m/z 1378.0
(calcd 1378.6); [M+K]+, m/z 1393.9 (calcd 1394.7).
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To a solution 7 (0.094 g, 0.069 mmol) in of 5 mL of MeOH and 10 mL of CHCl3 was added
20 mg Pd/C (10%). The mixture was placed in a Parr reactor bottle and rocked for 24 hours at
60 psi H2. Upon complete deprotection, the catalyst was filtered off using Celite and the
solvents were removed under reduced pressure. 8 was purified by recrystallization in MeOH/
CH2Cl2 in a quantitative yield. 1H NMR (MeOD, 400 MHz) δ 8.34 (s, 3H), 6.69 (s, 2H), 6.67
(s, 2H), 6.56 (d, 2H), 3.64 (t, 4H), 3.60 (t, 1H), 3.33 (s, 4H), 3.29 (t, 2H), 2.77 (t, 4H), 1.90
−1.50 (m, 4H), 1.27 (p, 2H); 13C NMR (CDCl3, 100 MHz) δ; 175.3, 174.1, 168.5, 146.1, 144.7,
136.6, 132.0, 129.4, 121.1, 117.0, 116.4, 68.2, 55.1, 43.1, 40.3, 35.9, 26.4, 25.9, 23.6. MALDI-
MS: [M+H]+, m/z 724.8 (calcd 725.7); [M+Na]+, m/z 746.8 (calcd 747.7).
Surface modification of iron oxide nanoparticles with bis-NTA-derived Ni(II) chelate and
mono-NTA-derived Ni(II) chelate
. The ligand 4 (0.5 mL of a 10 mg/mL MeOH solution) was placed in 1.25 mL distilled water.
To this aqueous solution was added 1 mL of iron oxide nanoparticles in n-hexanes (16.3 mg/
mL). The two layers were sonicated for 1 hour, and repeatedly washed with n-hexanes, then
methanol until the nanoparticles were readily dispersed in distilled water. Using a magnet, the
nanoparticles were collected and placed in 2 mL of distilled water. The bis-NTA-pendant
ligand-immobilized nanoparticles (0.5 mL) were placed in 2M NiCl2 solution and sonicated
for 1 hour. The Ni(II)-loaded nanoparticles were stored in the NiCl2 solution before use. Iron
oxide nanoparticle modified with mono-NTA Ni(II)-loaded nanoparticles were similarly
prepared.
Preparation of Ni(II)-loaded magnetic microparticles
An aliquot of 0.5 mL (2.4 μmol carboxyl) BioMag Carboxyl magnetic iron oxide microparticles
(∼1.5 μm mean diameter, ∼20 mg/mL particle concentration, ∼4.8 μmol/mL carboxy-surface
titration) was washed with distilled water (3×500 μL), then with acetone (3×500 μL). Aliquots
of N-hydroxysuccinimide (NHS) (25 μL, 30 mg/mL acetone) and dicyclohexylcarbodiimide
(50 μL, 50 mg/mL acetone) were added and incubated overnight. The NHS-activated particles
were washed with acetone and used without further purification.
A 240 μM solution of Nα,Nα-bis(carboxymethyl)-L-lysine was prepared by dissolving 0.629
mg Nα,Nα-bis(carboxymethyl)-L-lysine in 35 μL of triethylamine, 500 μL of acetone, and 500
μL of distilled water. The NHS-activated microparticles were washed with distilled water, then
placed in 100 μL of the Nα,Nα-bis(carboxymethyl)-L-lysine solution. After overnight
incubation, the particles were washed with distilled water. The particles were placed in a 1M
NiCl2 solution for 1 hour before use.
Isolation of recombinant mouse His×6-Endostatin (His×6-rmES) with Ni(II)-loaded
nanoparticles
The Ni(II)-loaded nanoparticles (7−10 μL; 16.3 mg/mL) were washed in distilled water (3×50
μL) and a binding buffer (3×50 μL; 50 mM phosphate buffer system, 300 mM NaCl, 10 mM
imidazole, pH 8.0). The washed nanoparticles were incubated with 10 μg of His×6-rmES in
40 μL of binding buffer for 5−60 minutes at 4 °C. Using a centrifuge and magnet, the
supernatant was collected and nanoparticles washed in 50 μL aliquots of binding buffer (FT:
Flow Through, W1: Wash 1, W2: Wash 2, W3: Wash 3). After the third wash, 50 μL of the
elution buffer (50 mM phosphate buffer system, 300 mM NaCl, 250 mM imidazole, pH 8.0)
was added and the mixture tumbled for 10 minutes at 4 °C. The eluents were similarly collected
by centrifugation and magnetic immobilization (E1: Elution 1, E2: Elution 2). Non-specifically
bound protein was released from the nanoparticles by boiling at 95 °C for 4 minutes in a
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Laemmli SDS-PAGE gel loading buffer. The volumes of the aliquots were reduced in a
Speedvac before loading to an SDS-PAGE (12.5%, 180V, 50 min). After separation, the SDS-
PAGE gel was stained in a Coomassie Blue solution (0.1% Coomassie blue, 10% acetic acid,
40% methanol) overnight. Recombinant human His×6-ubiquitin (His×6-Ub), and recombinant
mouse His×6-ubiquitin C-terminal hydrolase L-1 (His×6-UCH-L1) were isolated with Ni(II)-
loaded nanoparticles in the same fashion. Protein isolation by commercial magnetic agarose
beads was performed according to the manufacturer's instructions (Qiagen).
Isolation of His×6-rmES by Ni(II)-loaded microparticles
The Ni(II)-loaded microparticles (10 μL, 20mg/mL) were washed in distilled water (3×50 μL)
and binding buffer (3 × 50 μL). The washed microparticles were incubated with 10 μg of His×6-
rmES in 40 μL of binding buffer for 60 minutes at 4 °C. The beads were washed and the bound
protein eluted similarly. All the fractions were loaded to an SDS-PAGE for analysis as
previously described.
Expression of [35S]-methionine-labeled His×6-GMAP-210
The gene coding a 70 kDa fragment of GMAP-210 (Golgi-associated microtubule-binding
protein) was PCR-amplified from a human total RNA library (Stratagene). After introducing
the T7 promoter and TMV 5’-UTR by second PCR, the cDNA was used as template for a
coupled in vitro transcription/translation (TNT) reaction in the presence of 10 μCi [35S]-
methionine (Perkin-Elmer) in a total volume of 25 μL for 90 minutes at 30 °C. Protein synthesis
was confirmed by SDS-PAGE and autoradiography. The protein was stored at −80 °C until
used.
Isolation of [35S]-methionine-labeled His×6-GMAP-210 with Ni(II)-loaded nanoparticles
The Ni(II)-loaded nanoparticles (10 μL; 16.3 mg/mL) were washed in distilled water (3×50
μL) and binding buffer (3×50 μL). The washed nanoparticles were incubated with 5 μL of TNT
reaction mixture in 100 μL of binding buffer for 60 minutes at 4 °C. The nanoparticles were
washed and the bound protein eluted according to the procedures detailed above. All the
fractions including the remaining nanoparticles were transferred to scintillation vials for
radioactivity measurements using a liquid scintillation counter. Protein isolation using
commercial magnetic agarose beads (Qiagen) was performed according to the manufacturer's
instructions, and scintillation counts were measured as mentioned above.
Expression and purification of His×6-UGT from 293T cells using nanoparticles
The cDNA corresponding to the open reading frame of C. elegans UGT was amplified from a
C. elegans cDNA library (Invitrogen) using high fidelity Platinum Pfx DNA polymerase
(Invitrogen) and sequence-specific primers with CACC at the 5’ end of the forward primer.
The full-length cDNA was gel purified and subcloned into the pcDNA3.1D/V5-His TOPO
vector (Invitrogen) according to the manufacturer's instructions. The resulting gene-containing
plasmid was confirmed by PCR and sequence analysis.
293T cells were cultured in Dulbecco's Minimal Essential Media (DMEM, Gibco)
supplemented with 10% Fetal Bovine Serum (FBS, Sigma), 1% L-glutamate (Gibco), and 1%
Penicillin/Streptomycin. Cell culture was maintained at 37 °C with 5% CO2. On the day of
transfection, the pre-formed UGT plasmid DNA-Lipofectamine complex (500 μL) was added
directly to each well. Cells were incubated at 37 °C in 5% CO2 for 4 hours. Afterwards, the
media was changed and 2 mL of fresh DMEM (with 10% FBS and 1% L-glutamate) was added.
After incubation at 37 °C in a 5% CO2 incubator for a total of 24 hours to allow protein
expression, cells were harvested and lysed using a commercial extraction buffer (Biovision).
Intact cells were removed by centrifugation and the supernatants were cleared at 21,000×g for
Kim et al. Page 6













15 minutes at 4 °C. Levels of protein expression were assessed by separation on SDS-PAGE
gels, followed by Western blotting onto nitrocellulose membranes (Amersham Pharmacia),
and probing with anti-V5 antibody (Invitrogen). The lysates that were prepared were used for
binding studies.
To purify the His×6-UGT expressed in 293T cells, the pre-washed, Ni(II)-loaded nanoparticles
(10 μL; 16.3 mg/mL) were incubated with 50 μL of cleared crude cell lysate (∼4 μg/μL total
protein) in 50 μL of binding buffer for 15 minutes at 4 °C. After washing nanoparticles three
times using 50 μL of binding buffer, the bound proteins were eluted using 15 μL of elution
buffer. Aliquots of each fraction were loaded to an SDS-PAGE for separation. The protein was
detected by Coomassie blue staining.
RESULTS AND DISCUSSION
Surface Modification of Iron Oxide Nanoparticles with Bis-NTA and Mono-NTA Ni(II) Chelates
The iron oxide magnetic nanoparticles were synthesized using protocols previously described.
(12,13,14) The nanoparticles were washed in ethanol and transferred into n-hexanes and used
without further purification. The concentration of the nanoparticles was estimated based on
the dry mass after the removal of the solvents. Iron oxide nanoparticles prepared by different
routes gave similar results for protein binding and purification experiments.
Although a number of functional groups have been immobilized on iron oxide nanoparticles,
their binding strength and their ease of surface immobilization vary significantly. Since Xu
and co-workers recently demonstrated the efficient immobilization of dopamine derivatives
on iron oxide nanoparticles,(15) we have decided to use this strategy to immobilize bis-NTA
Ni(II) chelate for protein purifications. The new bis-NTA ligand with a catechol group (4) was
synthesized according to Scheme 1. Compound 4 was synthesized in 22% overall yield in 4
steps starting from known benzyl-protected dopamine trifluoroacetate salt and benzene-1,3,5-
tricarbonyltrichloride. New compounds 1−4 were characterized by 1H and 13C{1H} NMR
spectroscopy and mass spectrometry.
In order to determine the effects of multivalency on protein binding, we have also prepared a
new mono-NTA ligand with two catechol groups (8) by using a 1:1 ratio of dopamine
hydrochloride and benzene-1,3,5-tricarbonyltrichloride as shown in Scheme 2. Compound 8
was synthesized in an overall yield of 28% in 4 steps. New compounds 5−8 were characterized
by 1H and 13C{1H} NMR spectroscopy and mass spectrometry.
Surface modification of iron oxide nanoparticles with new NTA-derived ligands was
accomplished by simply stirring a biphasic mixture of the ligand in water and iron oxide
nanoparticles in hexanes. The NTA-ligand-immobilized nanoparticles were charged with Ni
(II) ions by ultrasonic mixing in 2M NiCl2. The iron oxide nanoparticles with different coatings
were characterized by transmission electron microscopy (TEM). TEM images of ∼10 nm
monodisperse iron oxide nanoparticles (prepared by thermal decomposition) before and after
surface modifications illustrate the retention of nanoparticle size and shape, and
monodispersity throughout monovalent and bivalent NTA-ligand surface modification and Ni
(II)-loading. Slight aggregation of Ni(II)-loaded nanoparticles was however observed in the
TEM images (Figure 1).
Binding of His×6-tagged Proteins Labeled with [35S]-Methionine
Immobilization of proteins onto the nanoparticles and subsequent elution were initially
demonstrated with His×6-tagged, [35S]-methionine-labeled GMAP-210 protein synthesized
via coupled in vitro transcription and translation (Scheme 3). In a typical binding-elution
experiment, the direct lysate (DL) signal is equal to the sum of the flow through (FT), washes
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(W1, W2, W3), elutions (E1, E2), and residual resin signals. The signal from each fraction was
measured using liquid scintillation counting.
Since only a small percentage of [35S]-methionine was incorporated into the recombinant
protein in the TNT reaction, a majority of the radioactivity in both the commercial beads and
nanoparticle systems came from unbound free [35S]-methionine in the FT (Figure 2 and Table
S1). Following the removal of FT, the resin was washed three times until the background was
low, before elution by imidazole. This scintillation counting assay demonstrates that the NTA-
modified nanoparticles can specifically capture His×6-tagged proteins followed by efficient
elution with imidazole. We also examined the relative protein binding capacity of nanoparticles
as compared to the commercial beads. It was found that the 10 μL (0.32% v/v suspension,
assuming Fe3O4 density of 5.15 g/cm3) of nanoparticle (16.3 mg/mL) had a similar binding
capacity to 10 μL (5% v/v suspension) of commercial magnetic agarose beads. It appears that
the unoptimized nanoparticles used in this work have higher residual radioactivity after elutions
when compared to the commercial beads, presumably due to relatively strong nonspecific
binding. This result was within expectation, since the commercial beads were coated with
agarose, which has low non-specific binding to proteins. We think that the non-specific binding
of the nanoparticle could be minimized if its surface is modified with hydrophilic molecules
such as PEG that are known to resist nonspecific protein binding.(16)
Binding of Overexpressed His×6-tagged Proteins
We next carried out protein binding studies of several commercially available recombinant
His×6-tagged proteins. One of the major problems in using Ni-NTA in protein purification is
that numerous His×6-tagged proteins can only be purified under denaturing conditions.
Consequently, a complicated refolding process is needed that often results in low yield of the
active protein. In this work, we focus on examining whether the NTA-modified nanoparticles
can be used under native conditions to purify His×6-tagged proteins that require denaturing
conditions when commercial NTA beads are used. We used recombinant murine His×6-
endostatin as an example. Endostatin is a potent angiogenesis inhibitor that has shown
therapeutic suppression of tumor-induced angiogenesis in mice implanted with tumors.(17)
O'Reilly et al. reported that recombinant murine endostatin with His×6 tag could be expressed
in E. coli as insoluble inclusion bodies and purified using Ni-NTA resin under denaturing
conditions. Endostatin thus purified underwent an inefficient refolding process before it could
be used in xenograft mouse studies. We found that the already folded endostatin could not be
captured when commercial Ni(II)-NTA beads were used. As shown in Figure 3, approximately
90% of His×6-rmES was present in the FT, and almost no protein was detected in the elutions,
indicating that commercial beads failed to capture His×6-rmES under native conditions.
Significantly, Ni(II)-loaded nanoparticles readily bound His×6-rmES without the use of
denaturing conditions. A 10 μL volume of Ni(II)-loaded nanoparticles (163 μg) is found to
have a binding capacity of 5.6 μg under unoptimized conditions. The His×6-rmES was readily
eluted by imidazole and was shown to be biologically active in inducing apoptosis in cow
pulmonary artery endothelial cells (Figure S1)(18). Confocal microscopic images showed
characteristic apoptotic rings for the cow pulmonary artery endothelial cells after annexin-V
PE staining. This result indicates that milligrams of a biologically active native protein can be
purified using approximately 30 mg of Ni(II)-loaded nanoparticles. We have also successfully
recycled and reused the modified nanoparticles in His×6-rmES binding without Ni(II)
reloading. The recycled nanoparticle appears to have a similar binding capacity to the pristine
sample based on SDS-PAGE analysis (Figure S2).
We also compared the binding of other His×6-tagged proteins that do not require denaturing
conditions for Ni-NTA based purifications. Ubiquitin is a protein found throughout all
eukaryotic cells and plays key roles in highly specific protein degradation. The small His×6-
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tagged ubiquitin (9.3 kDa) is expected to have an affinity for both the commercial beads as
well as the surface modified nanoparticles. SDS-PAGE analysis confirms the affinity of the
commercial beads and the Ni(II)-loaded nanoparticle (Table 1 and Figure S3). Densitometry
analysis shows the binding capacity of 20 μL (5% v/v suspension) of commercial beads is 1.1
μg His×6-Ub, while that of 10 μL (0.32% v/v suspension) of bis-NTA-Ni(II)-loaded
nanoparticle is 2.3 μg. In comparing the binding of 10 μL (0.32% v/v suspension) of
nanoparticle for His×6-rmES (21.3 kDa, 5.6 μg) and 6×His-Ub (9.3 kDa, 2.3 μg), it is estimated
that the binding capacity of the Ni(II)-loaded nanoparticles is approximate 25 pmol of proteins/
μL.
Binding studies on His×6-UCH-L1 (∼25 kDa) were also used to demonstrate the nanoparticle's
ability to capture His×6-enzymes (Table 1 and Figure S4). Binding capacities of 40 μL (5% v/
v suspension) of commercial beads and 10 μL (0.32% v/v suspension) of nanoparticle are 0.06
μg and 3.48 μg His×6-UCH-L1, respectively. One major concern in NTA microbeads based
protein purification is the large elution volume that requires additional concentration steps
before being used in the subsequent experiments. While lyophilization can be used to
concentrate most proteins, the process reduces the biological activity of many other proteins.
Ultra-filtration is another widely used method in volume reduction. However, the loss of
purified proteins could be significant, presumably due to nonspecific interactions with the
membrane. Our Ni(II)-loaded nanoparticles disperse well in aqueous solution, and therefore
significantly smaller elution volume can be used. This advantage eliminates the need of volume
reduction and makes it possible to directly use the proteins after purification. Our studies clearly
demonstrated that the present magnetic, recyclable nanoparticles are able to bind important
His×6-proteins in native, active conformations with a high capacity and thus show significant
advantages over the commercial microbeads. Since the chosen His×6-proteins have a wide
range of molecular weights (9387.6 − 74406.8 Da) and isoelectric points (5.43 − 9.33), we do
not believe that their binding to the present Ni(II)-loaded nanoparticles are due to simple
electrostatic interactions.
Purification of Recombinant His×6-tagged Proteins from Crude Mammalian Cell Lysate
Proteins expressed in mammalian cells are usually soluble and active, and therefore extremely
useful in studying their physiological significances. The biggest drawback is that their
expression levels are very low, making the purification challenging. The nanoparticle platform
was previously used for protein purification from E. Coli cell lysate,(15) in which proteins are
much more easily overexpressed. We investigated whether our NTA-loaded nanoparticles
could be used to purify recombinant proteins expressed in mammalian cells. 293T cells were
used to express a recombinant His×6-UGT protein. The lysate was prepared for purification
of 6×His-UGT protein by the bis-Ni(II)-NTA modified nanoparticles. Figure 4 shows the
staining of DL, FT, W3, E1, E2, and nanoparticle fractions and clearly indicates the purification
of desired His×6-tagged protein from the mammalian crude lysate. The elution E1 is
significantly cleaner than the direct lysate, with few impurities. These nonspecifically bound
impurities are probably due to proteins with many amino acid residues that can coordinate to
the immobilized metal ion. Nonetheless, the present nanoparticle system has shown great
promise in the purification of His×6-tagged proteins from crude mammalian cell lysates.
Nonspecific Interactions
Nonspecific interactions between the protein and nanoparticles do not appear to be significant
when the NTA nanoparticles are chelated with Ni(II). Table 1 shows approximately 8.7% of
His×6-rmES remained on the Ni(II) loaded bis-NTA-modified nanoparticles after elution,
slightly higher than that on commercial microbeads. Without the chelation of Ni(II), His×6-
rmES was found to have a high affinity for the bis-NTA-modified nanoparticle (Figure S5).
Densitometry measurements show that more than 45% of the 6×His-rmES was present in the
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sum of the washes and elutions, while 39% of the protein remained on the bis-NTA-modified
nanoparticles.
On the other hand, freshly prepared iron oxide nanoparticles (without surface modifications)
had little interaction with His×6-rmES. Over 70% of the 10 μg of loaded protein was detected
in the FT and over 90% was detected in the sum of the FT and washes. The nanoparticles
retained approximately 7% of the His×6-rmES after elution, a significant reduction from the
39% retention of Ni(II)-free bis-NTA-modified nanoparticles. The nonspecific interaction of
the rmES to the nanoparticle is thus a result of the surface modifications. To rule out the
potential role of residual oleic acid on the nanoparticle surface, we carried out a binding
experiment using particles without oleic acid stabilization. Nonspecific interaction was
observed for the oleic acid-free nanoparticles as well.
As the ratio of His×6-rmES (μg) to bis-Ni(II)-loaded NTA nanoparticle (mg) is increased from
10.2 to 61.3, the amount of non-specifically bound protein appears to remain constant (Figure
5). The specific his-tag binding to Ni(II)-NTA occurs after the full capacity of the nonspecific
interaction is reached at a 6×His-rmES (μg) to bis-Ni(II)-loaded NTA nanoparticle (mg) ratio
between 10.2 and 15.3. Maximum binding capacity of the nanoparticle via the His×6-tag
appears to have been reached with a His×6-rmES (μg) to bis-Ni(II)-loaded NTA nanoparticle
(mg) ratio of 61.3 since some 6×His-rmES is detectable in the FT.
Various attempts were made to block the nonspecific interaction of the target protein (Figure
S6). We first attempted to block the nonspecific binding with BSA. The surface modified
nanoparticles were pre-incubated with BSA before the His×6-rmES binding experiment was
performed. Unfortunately, BSA did not effectively block the His×6-rmES nonspecific binding.
An attempt of blocking the His×6-rmES nonspecific interaction of the nanoparticle with a
smaller protein (His×6-Ub) did not seem to result in any noticeable improvement by SDS-
PAGE analysis.
Surface Density of the Ni-NTA Chelates
The mono-NTA ligand with two dopamine anchors was synthesized to present monovalency
of the Ni(II)-NTA moiety onto the nanoparticle surface. Interestingly, an SDS-PAGE binding
assay of the mono-Ni(II)-NTA-modified nanoparticle showed a similarly effective binding
with His×6-rmES (Figure S7). Furthermore, we compared the mono- and bis-Ni(II)-NTA
ligand modified nanoparticles by elution with variable imidazole concentrations, and no
significant difference was observed. Unlike commercial Ni-NTA beads, the His×6-rmES could
not be eluted from the mono- and bis-Ni(II)-NTA-modified nanoparticles at a pH as low as 4.0
(without the use of imidazole, Figure S8). These results are suggestive of similar binding
affinity of mono- and bis-Ni(II)-NTA-modified nanoparticles, probably a result of high surface
coverage of mono-Ni(II)-NTA moieties.
To demonstrate the importance of high surface coverage, we conjugated Ni(II)-NTA to
micrometer-sized, carboxy-terminated commercial beads (∼1.5 μm diameter). NTA-lysine
was conjugated to the beads via the amide bond using the DCC/NHS coupling protocol. Upon
loading with Ni(II), these beads were found to bind His×6-rmES as effectively as mono- and
bis-Ni(II)-NTA modified nanoparticles (Figure S9). This experiment unambiguously supports
the notion that enhanced binding of His×6-tagged protein can be achieved by taking advantage
of the multivalency effect.
CONCLUSIONS
New bis-nitrilotriacetic acid (NTA) chelates with catechol anchors were synthesized and
immobilized on superparamagnetic iron oxide nanoparticles. When loaded with Ni(II), these
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NTA-immobilized nanoparticles were shown to bind His×6-tagged proteins in their native,
folded conformations with retained activity that commercial microbeads fail to bind under
identical conditions. A series of control experiments suggest that the multivalency strategy can
be utilized to enhance the binding of His×6-tagged proteins in their native, folded
conformations. We further demonstrated the selective purification of His×6-tagged proteins
from direct cell lysates by using the Ni(II)-loaded magnetic nanoparticles. The present platform
is capable of efficient purification of His×6-tagged proteins that are expressed at low level in
mammalian cells. This work thus presents a novel nanoparticle-based high-capacity protein
purification system with shorter incubation times, proportionally large washes, and
significantly smaller elution volumes compared to currently available microbeads.
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TEM images of monodisperse iron oxide nanoparticles (∼10 nm in diameter): A) Prepared by
thermal decomposition and stabilized with oleic acid; B) Modified with bis-NTA ligand; C)
Ni(II)-loaded bis-NTA nanoparticle; D) Modified with mono-NTA ligand; E) Ni(II)-loaded
mono-NTA nanoparticle. The scale bar is 50 nm.
Kim et al. Page 17














Graphical representation of [35S]-labeled His×6-GMAP-210 binding scintillation counting
assay for bis-Ni-NTA nanoparticles (solid bars) and commercial Ni-NTA agarose beads (open
bars). Fractions collected and radioactivity quantified in counts per minute (CPM), DL = Direct
Lysate, FT = Flow Through, W1 = Wash 1, W2 = Wash 2, W3 = Wash 3, E1 = Elution 1, E2
= Elution 2.
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Binding assay of His×6-rmES: (A) Commercial magnetic agarose beads (Qiagen): no protein
was bound to the bead or eluted by imidazole. Most of the protein was washed away unbound
in the FT. (B) Bis-Ni-NTA NPs: His×6-tag protein was bound and a majority was eluted from
the nanoparticles by imidazole. (C) Graphical representation of densitometry quantification of
SDS-PAGE gels.
Kim et al. Page 19














Mammalian Cell Lysate Fractionation. SDS-PAGE (12.5% separation gel) results of flag-
His×6-UGT expressed in 293T cells showing marker (M), direct lysate (DL, 10% dilution),
flow through (FT, 10%), wash 3 (W3), elution 1 (E1), elution 2 (E2), and protein residue on
nanoparticle (NP).
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Preference toward nonspecific interaction before his-tag—Ni-NTA interaction demonstrated
through increasing ratios of 6×His-rmES protein (μg) to bis-Ni-NTA nanoparticle (mg) A:
10.2, B: 15.3, C: 61.3. (M = Marker, FT = Flow Through, W1 = Wash 1, W2= Wash 2, Wash
3 = W3, E1 = Elution 1, E2 = Elution 2, NP = protein bound nonspecifically to nanoparticle.)
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